Abstract
Carboxypeptidase A (CPA) is one of the most extensively studied zinc proteases and serves as a prototypical enzyme for a large family of metalloproteases that play important roles in biological systems. CPA has been used as a model enzyme for developing design strategies of inhibitors that restrain the catalytic activity of zinc proteases. Recently, there has been made a remarkable progress in designing small molecule inactivators that inhibit the enzymic activity of CPA irreversibly by chemically modifying a functional group at the active site of the enzyme. Of these irreversible inhibitors mechanism-based inactivators are of special interest due to their high selectivity for target enzyme and long duration of enzyme inhibition. These inactivators have been designed rationally on the basis of established topology of the active site and catalytic mechanism of the enzyme. Chemistry inherent to the zinc ion at the active site of the enzyme has been exploited in the design. The present review covers the progress in the CPA inactivator design strategy. The design strategy developed with CPA may be transferred to other zinc proteases of medicinal interest, leading to discovery of a novel type of therapeutically useful enzyme inhibitors.
Keywords: Carboxypeptidase, proteases, zinc, enzyme inhibition
Current Topics in Medicinal Chemistry
Title: Chemistry-based Design of Inhibitors for Carboxypeptidase A
Volume: 4 Issue: 12
Author(s): Dong H. Kim
Affiliation:
Keywords: Carboxypeptidase, proteases, zinc, enzyme inhibition
Abstract: Carboxypeptidase A (CPA) is one of the most extensively studied zinc proteases and serves as a prototypical enzyme for a large family of metalloproteases that play important roles in biological systems. CPA has been used as a model enzyme for developing design strategies of inhibitors that restrain the catalytic activity of zinc proteases. Recently, there has been made a remarkable progress in designing small molecule inactivators that inhibit the enzymic activity of CPA irreversibly by chemically modifying a functional group at the active site of the enzyme. Of these irreversible inhibitors mechanism-based inactivators are of special interest due to their high selectivity for target enzyme and long duration of enzyme inhibition. These inactivators have been designed rationally on the basis of established topology of the active site and catalytic mechanism of the enzyme. Chemistry inherent to the zinc ion at the active site of the enzyme has been exploited in the design. The present review covers the progress in the CPA inactivator design strategy. The design strategy developed with CPA may be transferred to other zinc proteases of medicinal interest, leading to discovery of a novel type of therapeutically useful enzyme inhibitors.
Export Options
About this article
Cite this article as:
Kim H. Dong, Chemistry-based Design of Inhibitors for Carboxypeptidase A, Current Topics in Medicinal Chemistry 2004; 4 (12) . https://dx.doi.org/10.2174/1568026043387908
DOI https://dx.doi.org/10.2174/1568026043387908 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Editorial (Hot Topic:Current Situation at Perioperative of Cardiovascular Disease Patients: New Addressing and Perioperative Optimization Techniques)
Current Pharmaceutical Design SPMMTE and HPLC Methods for the Analyses of Cardiovascular Drugs in Human Plasma Using New Generation C28 Column
Current Pharmaceutical Analysis Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Total Sleep Duration and Risk of Type 2 Diabetes: Evidence-Based On Clinical and Epidemiological Studies
Current Drug Metabolism Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen
Vascular Disease Prevention (Discontinued) Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews Lipoxins, The Novel Mediators of Gastroprotection and Gastric Adaptation to Ulcerogenic action of Aspirin
Current Pharmaceutical Design Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Anti-Infective Drug Discovery Elucidation of the Mechanisms and Molecular Targets of Qishen Yiqi Formula for the Treatment of Pulmonary Arterial Hypertension using a Bioinformatics/Network Topology-based Strategy
Combinatorial Chemistry & High Throughput Screening